Citations

Clear

3138 citation(s) found for "Smith, AM".

Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils
Baldassarre, Lauren A. , Yang, Eric H. , Cheng, Richard K. , DeCara, Jeanne M. , Liu, Jennifer E. , Rudski, Lawrence , Strom, Jordan B. , Barac, Ana , Bucciarelli‐Ducci, Chiara , Lenneman, Carrie , Villarraga, Hector R. , Ismail‐Khan, Roohi , Ky, Bonnie , Leja, Monika, Scherrer‐Crosbie, Marielle , Liu, Jennifer E , Rudski, Lawrence G , Strom, Jordan B , Thavendiranathan, Paaladinesh , Barac, Ana , Zaha, Vlad G , Bucciarelli-Ducci, Chiara , Ellahham, Samer , Deswal, Anita M , Lenneman, Carrie , Villarraga, Hector R , Blaes, Anne H , Ismail-Khan, Roohi , Ky, Bonnie , Scherrer-Crosbie, Marielle , Yang, Eric , Cheng, Richard , Dent, Susan , Blaes, Anne

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 3, 2020 | Volume: 113 | Issue: 5 | Pages: 513-522

10.1093/jnci/djaa177 | PMID 33179744 Get It

Abstract In response to the coronavirus disease 2019 (COVID-19) pandemic, the Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this expert consensus statement. Cardio-oncology patients—individuals with an active or prior cancer history and with or at risk of cardiovascular disease—are a rapidly growing population who are at increased risk of infection, and experiencing severe and/or lethal complications by COVID-19. Recommendations for optimizing screening and monitoring visits to detect cardiac dysfunction are discussed. In addition, judicious use of multimodality imaging and biomarkers are proposed to identify myocardial, valvular, vascular, and pericardial involvement in cancer patients. The difficulties of diagnosing the etiology of cardiovascular complications in patients with cancer and COVID-19 are outlined, along with weighing the advantages against risks of exposure, with the modification of existing cardiovascular treatments and cardiotoxicity surveillance in patients with cancer during the COVID-19 pandemic.
Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group
Parzen, Jacob S. , Hartsell, William F. , Chang, John P., Molitoris, Jason K. , Durci, Michael, Urbanic, James J., Ashman, Jonathan B. , Vargas, Carlos , Stevens, Craig, Kabolizadeh, Peyman, Apisarnthanarax, Smith , Tsai, Henry K.

Mayo Clinic

No container title available | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-70862/v2 Get It

Abstract Background: Recent advances in radiotherapy techniques have allowed ablative doses to be safely delivered to inoperable liver tumors. In this setting, proton beam radiotherapy (PBT) provides the means to escalate radiation dose to the target volume while sparing the uninvolved liver. This study evaluated the safety and efficacy of hypofractionated PBT for liver tumors, predominantly hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).Methods: We evaluated the prospective registry of the Proton Collaborative Group for patients undergoing definitive PBT for liver tumors. Demographic, clinicopathologic, toxicity, and dosimetry information were compiled.Results: To date, 63 patients have been treated at 9 institutions between 2013-2019. Thirty (48%) had HCC and 25 (40%) had ICC. The median dose and biological equivalent dose (BED) delivered was 58.05 GyE (range, 32.5-75) and 80.5 GyE (range, 53.6-100), respectively. The median mean liver BED was 13.9 GyE. Three (4.8%) patients experienced at least one grade ³3 toxicity. With median follow-up of 5.1 months (range, 0.1-40.8), the local control (LC) rate at 1 year was 91.2% for HCC and 90.9% for ICC. The 1-year LC was significantly higher (95.7%) for patients receiving BED greater than 75.2 GyE than for patients receiving BED of 75.2 GyE or lower (84.6%, p = 0.029). The overall survival rate at 1 year was 65.6% for HCC and 81.8% for ICC. Conclusions: Hypofractionated PBT results in excellent LC, sparing of the uninvolved liver, and low toxicity, even in the setting of dose-escalation. Higher dose correlates with improved LC, highlighting the importance of PBT especially in patients with recurrent or bulky disease.
Added Benefit and Risk of an Additional Biopsy or Targeting With Contrast‐Enhanced Ultrasound for Patients With Renal Transplants
Dahiya, Nirvikar , Zhang, Nan , Heilman, Raymond L. , Stanton, Melissa, Young, Scott W. , Kriegshauser, J Scott , Stanton, Melissa L, Young, Scott W , Patel, Maitray D , Kriegshauser, J. Scott , Smith, Maxwell L. , Patel, Maitray D.

Mayo Clinic

Journal of Ultrasound in Medicine | October 26, 2020 | Volume: 40 | Issue: 8 | Pages: 1603-1611

10.1002/jum.15544 | PMID 33103276 Get It

ObjectivesTo determine whether renal transplant diagnoses substantially change when 2 biopsy sites are chosen and whether contrast‐enhanced ultrasound (CEUS) has value for targeting the second site.MethodsWe prospectively enrolled 40 patients undergoing ultrasound‐guided renal transplant biopsy within 2 years of transplant: 20, surveillance; and 20, for cause. A CEUS examination was performed to identify cortical regions with subjectively altered flow. One biopsy was performed at the operator‐preferred (primary) site regardless of CEUS findings. Another biopsy was done at a second location, either targeted to an area in which CEUS perfusion findings differed from the primary site (targeted) or at a random location (secondary) if no other area differed. Specimens were randomly labeled A or B; pathologists were blinded to the CEUS result and biopsy location. Location‐specific CEUS assessments were recorded. Pathologic results were compared, including acute and chronic Banff scores and any new findings from the targeted or secondary biopsy.ResultsForty patients were enrolled between January 2016 and December 2018. No location‐specific pathologic differences correlated with differences in CEUS assessments. The second biopsy provided additional information that changed management in 4 of 40 patients (10.0% [95% confidence interval, 2.8%–23.7%]). Major bleeding complications occurred in 3 of 40 (7.5%) patients.ConclusionsContrast‐enhanced ultrasound targeting was not useful. Major bleeding complications were higher than expected, possibly due to the additional biopsy away from the operator‐preferred location. Obtaining a second renal transplant biopsy from a substantially different area than the initial operator‐preferred location provided additional clinically useful information in 10% of patients.
Platelet transfusion: The effects of a fluid warmer on platelet function
Mattson, Melissa K., Groves, Cory, Christensen, Jon M. , Chen, Dong , Stubbs, James R. , Karon, Brad S. , Nuttall, Gregory A. , Smith, Mark M , Stubbs, James R , Nuttall, Gregory A , Chen, Dong , Smith, Mark M.

Mayo Clinic

Transfusion | October 20, 2020 | Volume: 61 | Issue: 1 | Pages: 52-56

10.1111/trf.16139 | PMID 33078463 Get It

BackgroundPlatelet (PLT) transfusions are an important component of hemostatic resuscitation. The AABB has published several guidelines recommending that PLT units should not be infused through blood warming devices.Study Design and MethodsThirty‐one units of hospital blood bank apheresis PLTs were obtained. PLT‐rich plasma (PRP) aggregometry and thromboelastography (TEG) were performed on the unit samples before and after the units were infused through a Ranger blood/fluid warming device.ResultsThere were no differences in any of the aggregometry results before and after infusion of the PLTs through the blood warmer (all P > .32). There was a significant reduction in the TEG maximum amplitude (MA) of 69.8 ± 7.9 mm before and 66.0 ± 8.8 mm after (P < .001) infusion of the PLTs through the blood warmer and α angle 61.8 ± 9.4° before and 59.3 ± 8.2° after (P = .044) infusion of the PLTs through the blood warmer, although both mean values were within normal range for the TEG and not clinically significant. There were very good correlations of aggregometry and TEG results before and after infusion of the PLTs through the blood warmer device.ConclusionThis study did not demonstrate significant deleterious effect on PLT function from infusing apheresis PLT units through a blood warming device by PRP aggregometry. We did detect a statistically significant—but not clinically significant—reduction in TEG MA and α angle. The prohibition of transfusing PLT units though the Ranger blood warming device is not indicated.
Peripheral Nerve Blockade with Combined Standard and Liposomal Bupivacaine in Major Lower‐Extremity Amputation
Dumitrascu, Catalina I. , Warner, Nafisseh S. , Stewart, Thomas M. , Amundson, Adam W. , Bruns, Danette, Hanson, Andrew C. , Schulte, Phillip J. , Brown, Michael , Niesen, Adam D. , Bruns, Danette L., Warner, Matthew A , Warner, Nafisseh , Smith, Mark M. , Brown, Michael J., Mantilla, Carlos B. , Warner, Matthew A.

Mayo Clinic

Pain Practice | October 15, 2020 | Volume: 21 | Issue: 3 | Pages: 299-307

10.1111/papr.12959 | PMID 33058387 Get It

AbstractBackground and ObjectivesOptimizing perioperative analgesia for patients undergoing major lower‐extremity amputation remains a considerable challenge. The utility of liposomal bupivacaine as a component of peripheral nerve blockade for lower‐extremity amputation is unknown.MethodsWe conducted an observational study comparing three different perioperative analgesic techniques for adults undergoing major lower‐extremity amputation under general anesthesia between 2012 and 2017 at an academic medical center: (1) no regional anesthesia, (2) peripheral nerve blockade with standard bupivacaine, and (3) peripheral nerve blockade with a mixture of standard and liposomal bupivacaine. The primary outcome of cumulative opioid oral morphine milligram equivalent utilization in the first 72 hours postoperatively was compared across groups utilizing multivariable linear regression.ResultsA total of 631 unique anesthetics were included for 578 unique patients, including 416 (66%) without regional anesthesia, 131 (21%) with peripheral nerve blockade with a mixture of standard and liposomal bupivacaine, and 84 (13%) with peripheral nerve blockade with standard bupivacaine alone. Cumulative morphine equivalents were lower in those receiving peripheral nerve blockade with combined standard and liposomal bupivacaine compared with those not receiving regional anesthesia (multiplicative increase 0.67; 95% CI 0.50 to 0.90; P = 0.007). There were no significant differences in opioid utilization between peripheral nerve blockade groups (P = 0.59).ConclusionsPeripheral nerve blockade is associated with reduced opioid requirements after lower‐extremity amputation compared with general anesthesia alone. However, the incorporation of liposomal bupivacaine is not significantly different to blockade employing only standard bupivacaine.
A scalable workflow for the human exposome
Hu, Xin , Liang, YongLiang, Juran, Brian D., Ma, Chunyu , Martin, Greg S. , Neujahr, David C., Lazaridis, N., Martin, Greg S , Walker, Douglas Ian , Liang, YongLiang, Smith, Matthew Ryan , Orr, Michael C. , Uppal, Karan , Marsit, Carmen J. , Go, Young‐Mi , Pennell, Kurt D. , Miller, Gary W. , Jones, Dean P.

Mayo Clinic

No container title available | October 9, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-83843/v1 Get It

Abstract Complementing the genome with an understanding of the human exposome is an important challenge for contemporary science and technology. Tens of thousands of chemicals are used in commerce, yet cost for targeted environmental chemical analysis limits surveillance to a few hundred known hazards. To overcome limitations which prevent scaling to thousands of chemicals, we developed a single-step express liquid extraction (XLE), gas chromatography high-resolution mass spectrometry (GC-HRMS) analysis and computational pipeline to operationalize the human exposome. We show that the workflow supports quantification of environmental chemicals in small human plasma (200 µL) and tissue (≤ 100 mg) samples. The method also provides high resolution, sensitivity and selectivity for exposome epidemiology of mass spectral features without a priori knowledge of chemical identity. The simplicity of the method can facilitate harmonization of environmental biomonitoring between laboratories and enable population level human exposome research with limited sample volume.
Response to Letter to the Editor from Chee et al: “Prevention of Adrenal Crisis: Cortisol Response to Major Stress Compared to Stress Dose Hydrocortisone Delivery”
Prete, Alessandro , Taylor, Angela E. , Smith, David J. , Foster, Mark , Köhler, Sibylle, Fazal-Sanderson, Violet, Komninos, John, O’Neil, Donna, Vassiliadi, Dimitra A. , Mowatt, Christopher J, Mihai, Radu , Fallowfield, Joanne L. , Lord, Janet M. , Keevil, Brian , Wass, John , Arlt, Wiebke , Arlt, Wiebke , Prete, Alessandro , Taylor, Angela E , Bancos, Irina , Annane, Djillali , Karavitaki, Niki

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 8, 2020 | Volume: 106 | Issue: 1 | Pages: e407-e408

10.1210/clinem/dgaa719 | PMID 33029637 Get It

Response to Letter to the Editor: “Prevention of Adrenal Crisis: Cortisol Response to Major Stress Compared to Stress Dose Hydrocortisone Delivery”
Prete, Alessandro , Taylor, Angela E. , Smith, David J. , Foster, Mark , Köhler, Sibylle, Fazal-Sanderson, Violet, Komninos, John, O’Neil, Donna, Vassiliadi, Dimitra, Mowatt, Christopher J, Mihai, Radu , Fallowfield, Joanne L. , Lord, Janet M. , Keevil, Brian , Wass, John , Arlt, Wiebke , Arlt, Wiebke , Prete, Alessandro , Taylor, Angela E , Bancos, Irina , Vassiliadi, Dimitra A. , Annane, Djillali , Karavitaki, Niki

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 7, 2020 | Volume: 106 | Issue: 1 | Pages: e404-e406

10.1210/clinem/dgaa712 | PMID 33027808 Get It

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Deininger, Michael W. , Shah, Neil P. , Altman, Jessica K. , Berman, Ellin , Bhatia, Ravi , Bhatnagar, Bhavana , Maness, Lori J., Mead, Monica , Metheny, Leland , Moore, Joseph O., Naqvi, Kiran , Oehler, Vivian G. , Pallera, Arnel, Patnaik, Mrinal M. , Pratz, Keith W. , Pusic, Iskra , Rose, Michal G., Snyder, David S., Sweet, Kendra , Thompson, James E. , Yang, David T. , Gregory, Kristina M., Sundar, Hema, Bhatia, Ravi , DeAngelo, Daniel J. , Gotlib, Jason , Hobbs, Gabriela , Mohan, Sanjay , Smith, B. Douglas , Talpaz, Moshe

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 6, 2020 | Volume: 18 | Issue: 10 | Pages: 1385-1415

10.6004/jnccn.2020.0047 | PMID 33022644 Get It

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.
Rate of infection following revision anterior cruciate ligament reconstruction and associated patient‐ and surgeon‐dependent risk factors: Retrospective results from MOON and MARS data collected from 2002 to 2011
Group, MARS, Brophy, Robert H. , Wright, Rick W. , Huston, Laura J. , Haas, Amanda K. , Anderson, Allen F., Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Mann, Barton J., Albright, John P., Amendola, Annunziato, Andrish, Jack T. , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cox, Charles L. , Creighton, R. Alexander , Dahm, Diane L., Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Giffin, J. Robert , Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Hosea, Timothy M., Johnson, David C. , Johnson, Timothy S. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, Chunbong, Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McAllister, David R. , McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Sherman, Orrin H. , Li, Xulei, Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, LTC Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., Wolf, Brian R. , York, James J. , Svoboda, Steven J. , Brophy, Robert H. , McCarty, Eric C , Group, MARS, Allen, Christina R. , DeBerardino, Thomas M. , Mann, Barton, Spindler, Kurt P , Stuart, Michael J., Campbell, John , Cooper, Jonathan M., David, Tal S. , Johnson, David C., Jones, Morgan H. , Owens, Brett D. , Shea, Kevin G. , Li, Xulei

Mayo Clinic

Journal of Orthopaedic Research | October 1, 2020 | Volume: 39 | Issue: 2 | Pages: 274-280

10.1002/jor.24871 | PMID 33002248 Get It

AbstractInfection is a rare occurrence after revision anterior cruciate ligament reconstruction (rACLR). Because of the low rates of infection, it has been difficult to identify risk factors for infection in this patient population. The purpose of this study was to report the rate of infection following rACLR and assess whether infection is associated with patient‐ and surgeon‐dependent risk factors. We reviewed two large prospective cohorts to identify patients with postoperative infections following rACLR. Age, sex, body mass index (BMI), smoking status, history of diabetes, and graft choice were recorded for each patient. The association of these factors with postoperative infection following rACLR was assessed. There were 1423 rACLR cases in the combined cohort, with 9 (0.6%) reporting postoperative infections. Allografts had a higher risk of infection than autografts (odds ratio, 6.8; 95% CI, 0.9–54.5; p = .045). Diabetes (odds ratio, 28.6; 95% CI, 5.5–149.9; p = .004) was a risk factor for infection. Patient age, sex, BMI, and smoking status were not associated with risk of infection after rACLR.